

ROYAL HOSPITAL FOR WOMEN	APPROVED: NCC QUALITY COMMITTEE
DEPARTMENT MANUAL: DIVISION OF NEWBORN SERVICES	DATE: 12 <sup>th</sup> May 2014

**NEWBORN USE ONLY  
GIVEN ON DOCTORS ORDER ONLY**

**HYDRALAZINE**

<b>DESCRIPTION</b>	Antihypertensive agent.
<b>USE</b>	Hypertension.
<b>PRESENTATION</b>	20mg/ml ampoules 25mg/ tablets
<b>DOSE</b>	IV 250-1000mcg/kg/dose 6-8 hourly titrated to response.  ORAL 500mcg/kg/dose 8 hourly increase as necessary to a maximum of 2-3mg/kg/dose 8 hourly.
<b>ROUTE</b>	IV via proximal IV bung Oral with feeds
<b>MONITORING</b>	heart rate blood pressure as per NCC blood pressure monitoring protocol 2010.
<b>ADVERSE EFFECTS</b>	Tachycardia, emesis, and temporary agranulocytosis in neonates. Nausea, lupus-like syndrome, GI irritation and bleeding, fever, rash, conjunctivitis and bone marrow suppression in adults.
<b>SOLUTION COMPATIBILITY</b>	5% and 10% dextrose, 0.9% sodium chloride
<b>TERMINAL INJECTION SITE COMPATIBILITY</b>	amino acid, dobutamine, heparin, hydrocortisone succinate, potassium chloride, prostaglandine
<b>INCOMPATIBILITY</b>	amynophylline, ampicillin, diazoxide, frusemide, phenobarbital

**REFERENCES**

Neonatal Formulary 5, Drug use in Pregnancy and First Year of Life, 2007, Blackwell Publishing  
Watkinson M. Hypertension in the Newborn baby. (Review) Arch Dis Child 2002;86:F78-81  
Young TE. Mangum B. Neofax 19<sup>th</sup> edition 2008